These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19877987)

  • 1. OROS methylphenidate-induced skin eruptions.
    Coskun M; Tutkunkardas MD; Zoroglu S
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):593-4. PubMed ID: 19877987
    [No Abstract]   [Full Text] [Related]  

  • 2. Quillivant XR--an extended release oral suspension of methylphenidate.
    Med Lett Drugs Ther; 2013 Feb; 55(1409):10-1. PubMed ID: 23381227
    [No Abstract]   [Full Text] [Related]  

  • 3. Focalin XR for ADHD.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):22-4. PubMed ID: 19305368
    [No Abstract]   [Full Text] [Related]  

  • 4. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
    McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl.
    Goetz M; Surman CB; Mlynarova E; Krsek P
    J Clin Psychopharmacol; 2012 Apr; 32(2):300-2. PubMed ID: 22388167
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of long-acting OROS methylphenidate on routine driving in young adults with attention-deficit/hyperactivity disorder.
    Cox DJ; Mikami AY; Cox BS; Coleman MT; Mahmood A; Sood A; Moore M; Burket R; Merkel RL
    Arch Pediatr Adolesc Med; 2008 Aug; 162(8):793-4. PubMed ID: 18678816
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe and effective methylphenidate therapy in a pediatric patient with glaucoma.
    Lewis H; Lewis J
    Atten Defic Hyperact Disord; 2012 Mar; 4(1):37-9. PubMed ID: 22311620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.
    McBurnett K; Starr HL
    Expert Opin Pharmacother; 2011 Feb; 12(2):315-24. PubMed ID: 21226641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Jornay PM -- evening-dosed methylphenidate for ADHD.
    Med Lett Drugs Ther; 2019 Aug; 61(1578):126-128. PubMed ID: 31386648
    [No Abstract]   [Full Text] [Related]  

  • 13. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
    Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
    [No Abstract]   [Full Text] [Related]  

  • 16. Transdermal methylphenidate (Daytrana) for ADHD.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
    [No Abstract]   [Full Text] [Related]  

  • 17. Transdermal methylphenidate system: old wine in a new bottle.
    Bukstein OG
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):661-5. PubMed ID: 19442029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cmap ADHD and comorbid aggression algorithm.
    Sharp BW
    J Am Acad Child Adolesc Psychiatry; 2007 Jan; 46(1):1. PubMed ID: 17195721
    [No Abstract]   [Full Text] [Related]  

  • 19. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689
    [No Abstract]   [Full Text] [Related]  

  • 20. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva.
    Silva RR
    Drugs; 2006; 66(8):1127-8; discussion 1128. PubMed ID: 16789798
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.